Chandrapuram Ponnusamy Radhakrishnan was sworn in as the 15th Vice President of India, succeeding Jagdeep Dhankhar.
Vice President V V Giri's resignation in 1969 triggered political upheavals that saw the ruling party defy its own presidential nominee, the expulsion of a sitting prime minister by her party president, and a historic split in the Indian National Congress, recounts Utkarsh Mishra.
I would like to renew our commitment to advancing the frontiers of science in drug discovery, says the chairman of Dr Reddy's Labs.
The S&P BSE Sensex shed 119 points to close at 27,977 and the Nifty50 dropped 45 points to finish at 8,591.
Marathi film folk were honoured at the Filmfare Awards Marathi 2025.
rediffGURU Dr Shakeeb Ahmed Khan, a physiotherapist with 13 years of experience, explains how you can prevent injuries and heal from physical pain.
Nine Indian Americans are running for the US House of Representatives, which includes a re-election bid by six of them while three are making their maiden foray into Congressional politics.
Notably, four portfolio companies-- Agnikul, ePlane, CynLr, and GalaxEye -- of deep-tech investor Speciale Invest made it to the list.
Bollywood stars Jacqueline Fernandez and Ishaan Khatter are slated to deliver perform at the grand finale.
'Nobody asked us to work on this. It was on our own that we decided to embark on this journey.'
Dr Jaishankar meets up with movie star John Abraham, who plays J P Singh, currently India's ambassador to Israel, in The Diplomat.
Enhertu currently costs around Rs 1.6 lakh per 100-milligram injection.
As the policy was going to be revised, the BCCI staff including the finance, operations and media department were not paid their daily allowances for the IPL and WPL but now that the policy has been formulated, their dues should be cleared soon.
NSE Nifty ended at 4,113, down 42 points.
It has currently pared gains on weakness in select stocks, and is now up 22 points at 4,655. The Nifty has advanced 10 points to 1,488.
Corporate earnings from blue-chips like HDFC Bank, ICICI Bank, Donald Trump's swearing-in as the US President, and trading activity of foreign investors are the key factors to drive equity markets this week, analysts said. Trump will be sworn in as the US president for a second term on Monday. This week, several key Nifty-50 companies, including BPCL, HDFC Bank, Hindustan Unilever, Dr Reddy's, UltraTech Cement, JSW Steel and ICICI Bank are scheduled to announce their financial results.
On Monday, LSG face Delhi Capitals in their season-opener in Visakhapatnam, the first of two DC's home matches to be played at the Dr YS Rajasekhara Reddy ACA-VDCA Stadium this season.
India is home to more than 100 million diabetics, and the demand for anti-diabetic drugs is on the rise -- the Rs 20,611 crore anti-diabetic drug market in India is growing at 9 per cent or so.
Indian drugmakers supply 47 per cent of the generic medicine requirements in the US, and tariffs would have increased prices in the US domestic market for patients, who are already dealing with drug shortages.
Only in the event of the RSS managing to force Modi into accepting a consensual candidate, will the party not continue to 'being' the 'next Congress', observes Nilanjan Mukhopadhyay.
Research and development (R&D) spending by BSE 100 companies has grown steadily, rising from 0.89 per cent of revenue in FY20 to 1.32 per cent in FY24, averaging around 1 per cent over the period in-between, according to data compiled from Bloomberg and company annual reports. Also, these companies more than doubled their R&D spending in absolute terms over these five years: From Rs 25,041 crore to Rs 63,072 crore. While this reflects a prioritisation of innovation, corporate R&D investment remains relatively conservative.
'Obesity is a raging conversation globally now, and manufacturing of generics will pick up after the patent expires.'
The tailwind of low price erosion in the US generics market, seen by domestic pharmaceutical companies in calendar year 2023 (CY23), may be reversing slowly, caution analysts. According to the latest data from US-based Centers for Medicare and Medicaid Services (CMMS), price erosion in calendar year 2024 (CY24) on a year-to-date (YTD) basis stood at a high of 15 per cent in the oral solid dosage (OSD) segment compared to a low of 1 per cent in CY23. This erosion, according to a report by Antique Stock Broking, was the highest in the last three years.
The November 5 US presidential elections, Federal Reserve interest rate decision, trading activity of foreign investors, and the upcoming quarterly earnings from domestic firms are the major triggers that would influence sentiments in the equity market this week, analysts said. In an eventful week ahead, a host of macroeconomic data announcements and global trends would also drive the markets, experts said. "The upcoming week is poised to be eventful on the global front.
Mohit displayed immense game awareness, taking a single to bring Ashutosh on strike, bringing down the equation to five runs in four balls.
Delhi Capitals have never won the IPL despite featuring top talent over the years. Under Axar Patel's leadership, they will hope IPL 2025 finally ends their title drought.
G V Prasad is elevated as chairman of Dr Reddy's Laboratories, a position held by the late K Anji Reddy, and he has big shoes to fill.
In recent months, several pharma multinational corporations (MNCs) are increasingly turning to Indian companies to expand market reach in the country's pharmaceuticals sector. Sanofi's partnerships with Dr Reddy's, Cipla, and Emcure, AstraZeneca and Mankind Pharma - teaming up for asthma medication distribution - are a few instances of this trend. This strategy allows MNCs to leverage established Indian networks and reach a wider audience. Indian companies also benefit from global brands and expertise, say analysts.
Do we have enough trained oncologists and medical professionals in India to man these over 4,500 beds in the public sector?
Given the possibilities that next year's assembly elections could throw up, Stalin told the state assembly that an interim report had to be submitted by January 2026. The outcomes may well find its way into the DMK's poll manifesto, thus seeking to keep the electoral focus still on the BJP-ruled Centre and Prime Minister Modi, observes N Sathiya Moorthy.
Industry insiders in India warn that any such move in the pharmaceutical sector could be counterproductive for the US as it may face increased drug shortages if tariffs are imposed on such imports.
K Anji Reddy from a small village near Vijaywada, quit his job with the government-owned Indian Drugs and Pharmaceuticals Limited in 1974 to set up his own company. The rest is history.
Simvastatin goes off patent in late June; Ranbaxy gets 180-day exclusivity period; Dr Reddy's-Merck will be third player.
'In his demise, the world of Telugu language and literature has lost a bright star. The void caused by his loss can never be filled.'
With their respective leaders switching camps and squads undergoing major overhauls, both Delhi Capitals and Lucknow Super Giants, under new captains, will be eager to make a strong start to their IPL campaign when they face off in Visakhapatnam on Monday.
Dr Reddy, an innovative technocrat par excellence, led from the front the countless initiatives of his famed laboratory in discovering many effective, affordable, cures for the numerous ailments of mankind, writes Shreekant Sambrani.
With the bidding for the generics business of Merck set to begin from Monday, domestic pharmaceutical companies in the fray, Ranbaxy Laboratories and Dr Reddy's Laboratories, are unlikely to go for an all-out bidding war.
These are the top buyers of the scrapped electoral bonds, the data for which was released by the Election Commission on Thursday.
'There is no doubt he is with the Lord in heaven. He loved people and people poured their love on him. It was the people's love that got him elected as chief minister for a second term.'
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances